A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

Launched by ALK-ABELLÓ A/S · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for people in China who have allergies caused by house dust mites, which often lead to symptoms like sneezing, runny nose, and itchy, watery eyes. The treatment being tested is a tablet that you take under your tongue, called a SLIT-tablet, designed to help reduce allergy symptoms over time.

The study is looking for participants between 12 and 65 years old who have a history of allergic rhinitis (nasal allergy symptoms) caused by house dust mites and who still experience symptoms even after using allergy medicines in the past year. To join, participants must have had allergy symptoms most days during a recent two-week period and show positive allergy tests for dust mites. People with very severe asthma or certain other health conditions won’t be able to join. If you participate, you can expect to take the tablet regularly and be monitored to see if your allergy symptoms improve and if the treatment is safe. This study is not yet open for enrolling participants but aims to find better ways to manage house dust mite allergies in Chinese patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female Chinese subjects aged 12-65 years
• • A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening
• • Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period
• • Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period
• • Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening
• • Lung function ≥ 70% of predicted value
• Exclusion Criteria:
• • Sensitised and regularly exposed to perennial allergens
• • Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation
• • Asthma requiring treatment with high dose of inhaled corticosteroid
• • A relevant history of systemic allergic reaction